295 related articles for article (PubMed ID: 31136112)
1. Detection of clinically signifi cant prostate cancer with PIRADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions.
Westphalen AC; Fazel F; Nguyen H; Cabarrus M; Hanley-Knutson K; Shinohara K; Carroll PR
Int Braz J Urol; 2019; 45(4):713-723. PubMed ID: 31136112
[TBL] [Abstract][Full Text] [Related]
2. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
3. Can combined multiparametric magnetic resonance imaging of the prostate and prostate-specific antigen density improve the detection of clinically significant prostate cancer: A prospective single-center cross-sectional study.
Yadav K; Sureka B; Elhence P; Choudhary GR; Pandey H; Garg PK; Yadav T; Khera PS
J Cancer Res Ther; 2021; 17(2):372-378. PubMed ID: 34121679
[TBL] [Abstract][Full Text] [Related]
4. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
5. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
6. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.
Brizmohun Appayya M; Sidhu HS; Dikaios N; Johnston EW; Simmons LA; Freeman A; Kirkham AP; Ahmed HU; Punwani S
Br J Radiol; 2018 Feb; 91(1083):20170645. PubMed ID: 29189042
[TBL] [Abstract][Full Text] [Related]
7. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
8. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
9. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
10. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
[TBL] [Abstract][Full Text] [Related]
11. Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis.
Feng X; Chen X; Peng P; Zhou H; Hong Y; Zhu C; Lu L; Xie S; Zhang S; Long L
BMC Urol; 2024 Feb; 24(1):40. PubMed ID: 38365673
[TBL] [Abstract][Full Text] [Related]
12. MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort.
Washington SL; Baskin AS; Ameli N; Nguyen HG; Westphalen AC; Shinohara K; Carroll PR
AJR Am J Roentgenol; 2020 Mar; 214(3):574-578. PubMed ID: 31913068
[No Abstract] [Full Text] [Related]
13. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
[TBL] [Abstract][Full Text] [Related]
14. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
Akpinar C; Oz DK; Oktar A; Suer E; Ozden E; Haliloglu N; Gulpinar O; Gokce MI; Gogus C; Baltaci S
Clin Genitourin Cancer; 2024 Jun; 22(3):102071. PubMed ID: 38555682
[TBL] [Abstract][Full Text] [Related]
15. PI-RADS v2 and ADC values: is there room for improvement?
Jordan EJ; Fiske C; Zagoria R; Westphalen AC
Abdom Radiol (NY); 2018 Nov; 43(11):3109-3116. PubMed ID: 29550953
[TBL] [Abstract][Full Text] [Related]
16. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer.
Lokeshwar SD; Nguyen J; Rahman SN; Khajir G; Ho R; Ghabili K; Leapman MS; Weinreb JC; Sprenkle PC
Urol Oncol; 2022 Sep; 40(9):407.e21-407.e27. PubMed ID: 35811206
[TBL] [Abstract][Full Text] [Related]
18. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
19. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer.
Gündoğdu E; Emekli E; Kebapçı M
Radiol Med; 2020 Sep; 125(9):827-837. PubMed ID: 32266690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]